UroGen Pharma Ltd. expects profitability and positive cash flow in the fourth quarter of this year despite a $1.5 million Q3 net loss and a $5 million PDUFA fee.
URGN · UroGen Pharma Ltd.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Urogen Pharma reported $89 million in revenue, expects profitability and positive cash flow in the fourth quarter of 2026, and received FDA acceptance of UGN 103 with a June 14, 2027 PDUFA goal date.
UroGen reported revenue of 89,001 thousand dollars for the quarter ended September 30, 2026, up from 27,482 thousand a year earlier. Its net loss narrowed to 1,462 thousand dollars from 33,347 thousand, and cash and marketable securities totaled $90.5 million as of September 30, 2026. The company believes it has sufficient cash to fund operations beyond one year.
UroGen reported $68.0 million in third-quarter ZUSDURI revenue, up 35% from the second quarter of 2026, as the FDA accepted UGN-103's NDA for review with a June 14, 2027 PDUFA target date.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. ZUSDURI revenue grew 35% sequentially as prescriber breadth and repeat utilization increased; total revenue rose to $89.0 million, and management expects fourth-quarter profitability and positive cash flow. JELMYTO revenue and guidance declined amid unfavorable adjustments and clinical-trial enrollment headwinds, while operating expenses are expected near the upper end of guidance and R&D, SG&A, and interest expense increased.
- + ZUSDURI generated $68.0 million in third-quarter 2026 revenue, representing 35% sequential growth.
- + ZUSDURI adoption broadened and deepened, with 662 unique prescribers and 331 repeat prescribers.
- + Total revenue increased to $89.0 million from $27.5 million in the prior-year quarter.
- + The FDA accepted the UGN-103 NDA and assigned a PDUFA target action date of June 14, 2027.
- + Management expects to achieve profitability and generate positive cash flow in the fourth quarter of 2026.
- + A new patent is expected to provide coverage into July 2044 for ZUSDURI and, if approved, UGN-103.
- − JELMYTO third-quarter revenue declined to $21.0 million from $25.7 million in the prior-year quarter.
- − Full-year JELMYTO revenue guidance was reduced to approximately $90 million from $97 million to $101 million.
- − Full-year operating expenses are now expected near the upper end of the $260 million to $270 million range.
- − Third-quarter R&D expenses increased to $26.0 million from $14.0 million in the prior-year quarter.
- − Third-quarter SG&A expenses increased to $47.2 million from $37.6 million in the prior-year quarter.
- − Long-term debt interest expense increased to $4.8 million from $3.4 million in the prior-year quarter.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| activated sites of care | 1,444 | Q2 2026 | — |
| repeat ZUSDURI prescribers | 204 | Q2 2026 | — |
| repeat ZUSDURI prescribers as percent of total prescribers | 45% | Q2 2026 | — |
| unique ZUSDURI prescribers | 452 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
URGN
this stock
UroGen Pharma Ltd.
|
$1.46B | +27.2% | -86.2% | — | 10.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 20
UroGen Pharma Ltd. expects profitability and positive cash flow in the fourth quarter of this year despite a $1.5 million Q3 net loss and a $5 million PDUFA fee.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| URGN | +14.1% | -16.0% | +5.9% | -9.0% | +27.2% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +18.0% | -10.5% | +9.4% | -5.6% | +20.1% |